The Use of Immersive Virtual Reality as a Method of Treating Anxiety and Procedural Pain During Endovenous Laser Ablation (EVLA) of Lower Varicose Veins Under Tumescent Anesthesia (EVLA+VR)
Aperçu de l'étude
Statut
Les conditions
Intervention / Traitement
Description détaillée
This prospective single-arm interventional study with a pre-post design aims to assess the effect of immersive virtual reality (VR) on procedural anxiety, pain perception, cybersickness, sense of presence, usability, and overall patient satisfaction during ambulatory endovenous laser ablation (EVLA) performed under tumescent local anesthesia (TLA).
All consenting adult patients scheduled for unilateral or bilateral EVLA of the great saphenous vein (GSV), small saphenous vein (SSV), or accessory veins due to symptomatic chronic venous insufficiency (CEAP C2-C6) will be enrolled. There is no control group: every participant who provides informed consent will receive immersive VR (using a head-mounted display with relaxing/immersive nature-based content) starting 5-10 minutes before tumescent infiltration and continuing throughout the procedure (~30-60 minutes).
Key outcome measures will be collected at multiple time points:
Baseline (pre-procedure): hemodynamic parameters, saturation, technology experience, baseline anxiety and pain (VAS / NRS), every 5 minutes during the procedure and right after the surgical procedure, cybersickness (SSQ), satisfaction and any adverse events.
Technology-Focused Objective
• To evaluate usability and tolerability of VR technology in a real clinical setting, including:
- comfort of use during a medical procedure
- interaction with the device during limited mobility
- feasibility of VR integration into procedural workflow
Follow-up (4-6 weeks): delayed pain, satisfaction, technology experience, and adverse events.
The primary endpoint is the change in procedural anxiety (VAS) from pre- to post-procedure. Secondary endpoints include change in pain (NRS) and hemodynamic profile, cybersickness severity, presence scores, usability, patient satisfaction, and safety profile of VR in this setting.
Type d'étude
Inscription (Estimé)
Phase
- N'est pas applicable
Contacts et emplacements
Lieux d'étude
-
-
-
Bydgoszcz, Pologne, 85-796
- Bydgoszcz Univ of Science and Technology
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
La description
Inclusion Criteria:
- adults people scheduled to EVLA under local anesthesia and signed for VR interventiion.
Exclusion Criteria:
- exclusion of epilepsy, severe motion sickness, previous severe cybersickness
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Soins de soutien
- Répartition: N / A
- Modèle interventionnel: Affectation à un seul groupe
- Masquage: Aucun (étiquette ouverte)
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Expérimental: Adult patients, scheduled to EVLA procedure under local anesthesia.
exclusion of epilepsy, severe motion sickness, previous severe cybersickness
|
Immersive Virtual reality
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Procedural anxiety
Délai: Baseline (0), at the beginning of surgical procedure (1), at the end of surgical procedure (2) to the end of treatment at 8 weeks (3).
|
Visual Analogue Scale (VAS), 0-10 points, 0-no anxiety, 10-max anxiety level.
Higher scores mean worse outcome.
|
Baseline (0), at the beginning of surgical procedure (1), at the end of surgical procedure (2) to the end of treatment at 8 weeks (3).
|
|
Level of procedural pain
Délai: Baseline (0), at the beginning of surgical procedure (1), at the end of surgical procedure (2).
|
Visual Analogue Scale (VAS), 0-10, 0- no pain, 10-max pain ever.
Higher scores mean a worse outcome.
|
Baseline (0), at the beginning of surgical procedure (1), at the end of surgical procedure (2).
|
|
Heart Rate
Délai: Baseline, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
Heart Rate is the number of times a heart beats in one minute (bpm).
Normal heart rate is 60-100 bpm.
|
Baseline, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
|
Cybersickness severity
Délai: Day 1- after completing the surgical procedure.
|
SSQ The Simulator Sickness Questionnaire is the standard tool used to measure cybersickness. Patients rate 16 symptoms on a scale from 0 to 3- no, moderate, severe. These scores are mathematically weighted and aggreagated into a total scowe ranges 0-48 points. 0-5 severity level negligible, no symptoms, the VR experience is perfectly comfortable. 5-10 severity evel minimal, mild discomfort 10-15 significant, definitive sensory mismatch, patients may experiance slight nausea or disorientation 15-20 concerning, noticeable sickness, the experiance is moderately uncomfortable more than 20- high, the VR application causes severe discomfort and requires a redesign to reduce visual motion. Higher scores mean a worse outcome. The 16 symptoms are mapped into 3 subscales: nausea or stomach awareness, occulomotor- eye strain and difficulty focusing, disorientation- dizziness, vertigo, |
Day 1- after completing the surgical procedure.
|
|
Patient satisfaction
Délai: From enrollment to the end of treatment at 8 weeks"
|
SUS- usability questionnaire is the system usability scale, which measures the feeling of usability of the users when using computer systems, navigate patient portals, telemedicine platforms, or self-management apps. A reliable tool that measures how easy to use, complex, or efficient a patient or user finds a digital health application. It is composed of 10 questions with a five-point Likert attitude scale (from strongly disagree to strongly agree), typically ranging from 1 ("Not at all") to 5 ("Very much"). Calculation: Scores range from 0 to 100. A score above 68 is generally considered above-average usability. |
From enrollment to the end of treatment at 8 weeks"
|
|
Systolic blood pressure
Délai: From enrollment, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
Systolic blood pressure measures the maximum pressure of blood exerts against your artery walls when your heart beats and pumps blood out to the body. Key Ranges (in mm Hg) Normal: Below 120, Elevated: 120-129, Hypertension (High Blood Pressure): 130 or higher. |
From enrollment, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
|
Diastolic blood pressure
Délai: From enrollment, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
Diastolic blood pressure is the bottom (lower) number in a blood pressure reading.
It measures the minimum pressure exerted against artery walls when a heart muscle is resting and refilling with blood between beats.
A standard blood pressure reading is measured in millimeters of mercury (mm Hg).
According to standard cardiovascular guidelines, blood pressure is categorized by the following diastolic ranges:Normal: Less than \(80\) mm Hg.Elevated: Less than \(80\) mm Hg (with systolic between \(120-129\)).Hypertension Stage 1: \(80-89\) mm Hg.Hypertension Stage 2: \(90\) mm Hg or higher.Hypertensive Crisis: Higher than \(120\) mm Hg.
|
From enrollment, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
|
Oxygen saturation
Délai: From enrollment, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
Oxygen saturation measured by Pulse Oximetry Sp02 measures the percentage of hemoglobin in red blood cells that is actively carrying oxygen.
It indicates how effectively is blood transports oxygen from the lungs throughout the body.Typical Ranges & Interpretation Normal Range: 95% to 100% for a healthy adult.
Low (Hypoxemia): Values below 90% are considered low and typically require external oxygen supplementation or medical evaluation.
|
From enrollment, at the beginning of surgical procedure and every 5 minutes during EVLA and in the end of surgical procedure.
|
Collaborateurs et enquêteurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Estimé)
Achèvement primaire (Estimé)
Achèvement de l'étude (Estimé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- VR
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Description du régime IPD
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .